Linked Life Data

10590363

Source:http://linkedlifedata.com/resource/pubmed/id/10590363

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2000-1-5
pubmed:abstractText
To assess whether the addition of cisplatin (100 mg/m(2) administered intravenously on Day 1) to CDE (cyclophosphamide [1000 mg/m(2) on Day 1], doxorubicin [45 mg/m(2) on Day 1], and etoposide [150 mg/m(2) on Days 1 and 2] combination is useful in the treatment of patients with small cell lung carcinoma (SCLC).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0008-543X
pubmed:author
pubmed:copyrightInfo
Copyright 1999 American Cancer Society.
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
86
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2238-45
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. "Petites Cellules" Group.
pubmed:affiliation
Service de Pneumologie, Hôpital St. Antoine, Faculté de Médecine St. Antoine, Université Paris VI, Paris, France.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Multicenter Study